XP Inc. (XP)
NASDAQ: XP · Real-Time Price · USD
16.36
+0.21 (1.33%)
At close: Aug 1, 2025, 4:00 PM
16.68
+0.32 (1.99%)
After-hours: Aug 1, 2025, 7:48 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 5 analysts that cover CTI BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $23.8, which forecasts a 45.52% increase in the stock price over the next year. The lowest target is $19 and the highest is $29.
Price Target: $23.80 (+45.52%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 10, 2025.
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 2 | 2 | 2 |
| Hold | 3 | 3 | 3 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $17 → $24 | Strong Buy | Maintains | $17 → $24 | +46.74% | Jun 10, 2025 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades $17 → $23 | Hold → Strong Buy | Upgrades | $17 → $23 | +40.63% | Jun 4, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $15 → $17 | Hold | Maintains | $15 → $17 | +3.94% | May 21, 2025 |
| B of A Securities | B of A Securities | Hold Maintains $16 → $19 | Hold | Maintains | $16 → $19 | +16.17% | May 21, 2025 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $18 → $24 | Hold → Buy | Upgrades | $18 → $24 | +46.74% | May 13, 2025 |
Financial Forecast
Revenue This Year
19.29B
from 16.25B
Increased by 18.70%
Revenue Next Year
21.79B
from 19.29B
Increased by 12.98%
EPS This Year
9.70
from 8.23
Increased by 17.90%
EPS Next Year
11.18
from 9.70
Increased by 15.24%
Financial currency is BRL. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 20.6B | 23.4B | 26.0B | |
| Avg | 19.3B | 21.8B | 24.3B | |
| Low | 17.9B | 20.0B | 22.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 26.8% | 21.2% | 19.3% | |
| Avg | 18.7% | 13.0% | 11.5% | |
| Low | 10.0% | 3.8% | 2.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 10.24 | 11.88 | 13.42 |
| Avg | 9.70 | 11.18 | 12.77 |
| Low | 8.79 | 10.22 | 11.78 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 24.4% | 22.4% | 20.0% |
| Avg | 17.9% | 15.2% | 14.2% |
| Low | 6.7% | 5.3% | 5.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.